Recipharm Biologics and Cobra Biomanufacturing plc Combine
News Feb 23, 2010
Recipharm AB has announced that following the successful acquisition of Cobra Biomanufacturing plc, it has now combined it with the existing Biologics activities located in Sweden. The integrated business will be known as RecipharmCobra Biologics and will operate as Recipharm’s specialist biologics division.
The combination of both companies capabilities creates a biological service offering, encompassing cell line development, analytical and process development and GMP production of recombinant proteins, DNA, viruses and cell products for Phase I, II and III clinical trials. This, together with fill-finish and formulation capabilities, provides customers with a true one stop shop concept for their biologics outsourcing needs.
Simon Saxby, former CEO of Cobra Biomanufacturing, will head up RecipharmCobra Biologics in the newly formed position of Vice President, Biologics.
With the integration complete, RecipharmCobra Biologics will have cGMP approved production facilities in Keele and Oxford, UK and Sodertalje, Sweden.
RecipharmCobra Biologics holds significant IP and licenses in expression technologies, including ORT-VAC and UCOE, platform expression technologies that deliver cost effective production of customer materials.
Thomas Eldered, CEO of Recipharm AB commented: “Integrating the experience of Cobra Biomanufacturing’s staff, expertise and established services with our own previous offering has, we believe, created a much stronger force in the industry’s biologics outsourcing sector. Indeed, in addition to antibodies and rProteins, our integrated company competitively offers both process development and cGMP manufacturing services for viruses, DNA and cells.”
He added: “The move will also serve to further build our position as a leading Contract Development and Manufacturing Organization that provides a full range of high quality services.”
Two proteins that activate the fastest molecule in our nerve cells have been identified by researchers at University of Warwick. This mechanism is responsible for transport through our nervous system. This finding could lead to a new therapeutic treatments for people with hereditary spastic paraplegia and other neurological disorders.READ MORE
There are currently no drugs that stop or inhibit Alzheimer's disease. Despite drug trials showing plaque reduction in the brain, the patients' cognitive function did not improve. Would the results be different if it were possible to design studies that intervene much earlier on in the disease, before cognition is affected?READ MORE